Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases

Ryan Limbocker, Nunilo Cremades, Roberta Cascella, Peter M. Tessier, Michele Vendruscolo, Fabrizio ChitiAccounts 2023 · DOI

TL;DR

This paper presents a powerful approach to understanding protein misfolding diseases by comparing pairs of toxic and non-toxic protein oligomers. By dissecting the structural and physicochemical differences between these closely related species, researchers have identified key features, like exposed hydrophobic regions and membrane interaction, that dictate their cellular toxicity, paving the way for targeted therapeutic strategies.

What Problem Does This Paper Address?

Protein misfolding and aggregation are at the heart of numerous devastating neurodegenerative diseases, including Alzheimer's and Parkinson's. While amyloid plaques and fibrils are well-known hallmarks, growing evidence points to smaller, transient species called oligomers as the primary culprits driving cellular dysfunction and death. However, studying these oligomers is incredibly challenging due to their instability, low concentrations, and structural heterogeneity. This makes it difficult to pinpoint exactly why some oligomers are toxic and others are not, hindering the development of effective treatments. This paper addresses this challenge by focusing on the creation and comparative analysis of "toxic vs. non-toxic" oligomer pairs from the same protein, allowing for a direct interrogation of the molecular determinants of toxicity.

Methods

The core of this work lies in the ability to generate and stabilize pairs of morphologically similar but functionally distinct (toxic vs. non-toxic) protein oligomers. This was achieved through carefully controlled incubation conditions and the use of stabilizing small molecules. Once these stable pairs were obtained, a multidisciplinary approach was employed, integrating:

  • Biophysical techniques: Atomic Force Microscopy (AFM) for morphology, Thioflavin-T (ThT) binding for amyloid structure, and Nuclear Magnetic Resonance (NMR) spectroscopy (both solution-state and solid-state) for detailed structural characterization.
  • Biochemical assays: Fluorescence spectroscopy (e.g., using ANS and pyrene labeling) to probe solvent exposure of hydrophobic regions and structural order.
  • Cell-based assays: Measuring cellular responses like Ca2+ influx, membrane integrity disruption, and cell death (e.g., MTT reduction, Calcein release).
  • In vivo models: Using animal models (e.g., C. elegans, rat brains) to assess the physiological impact of oligomers.

The novelty lies not in individual techniques, but in their systematic application to these precisely defined toxic/non-toxic pairs, enabling direct correlation of structural features with functional outcomes.

Datasets

Not discussed in the paper. The paper focuses on experimental generation and characterization of protein oligomers rather than utilizing pre-existing datasets for training or evaluation.

Key Insights and Ideas

  • The "toxic vs. non-toxic" pair is a powerful paradigm: By comparing oligomers derived from the same protein under slightly different conditions, researchers can isolate the specific structural and physicochemical features responsible for toxicity, rather than being confounded by general aggregation properties.
  • Hydrophobicity is a major driver of toxicity: Exposed hydrophobic regions on the surface of toxic oligomers appear to be critical for their ability to interact with and disrupt cell membranes. Non-toxic oligomers tend to bury these hydrophobic residues.
  • Membrane interaction is key: Toxic oligomers actively engage with and destabilize lipid bilayers, leading to downstream cellular events like calcium influx. Non-toxic oligomers either don't interact or do so in a way that doesn't cause significant harm.
  • Structure matters, but not always in the expected way: While some toxic oligomers have more organized cores, the presence of solvent-exposed hydrophobic patches seems to be a more consistent predictor of toxicity than overall β-sheet content or compactness alone.
  • Oligomer size is inversely related to toxicity: Smaller oligomers are generally more toxic, likely due to their increased ability to interact with and penetrate membranes.

Key Results

The study successfully characterized four distinct pairs of toxic and non-toxic oligomers from HypF-N, Aβ42, α-synuclein, and Sup35 NM. Key findings include:

  • HypF-N: Toxic oligomers (Type A) showed higher solvent-exposed hydrophobicity and greater ability to penetrate cell membranes compared to non-toxic Type B oligomers.
  • Aβ42: Toxic A+ oligomers were less stable and had increased solvent-accessible hydrophobic segments, leading to greater membrane disruption and cellular toxicity than non-toxic A- oligomers.
  • α-synuclein: Toxic B oligomers exhibited a β-sheet rich core and N-terminal segment that facilitated membrane insertion and disruption, while non-toxic A oligomers were largely disordered and inert.
  • Sup35 NM: Toxic A11+ oligomers were found to be less compact and more hydrophobic than non-toxic OC+ oligomers, correlating with their higher toxicity.

Across these systems, toxic oligomers consistently demonstrated higher exposed hydrophobicity, greater membrane affinity, and a stronger ability to disrupt cell membranes and induce dysfunction.

Limitations and Future Work

The authors acknowledge that while these studies provide crucial insights, the specific mechanisms of toxicity can vary between different protein systems. Future work will involve:

  • Expanding the repertoire: Developing and studying toxic/non-toxic oligomer pairs from other proteins implicated in misfolding diseases.
  • Refining therapeutic strategies: Leveraging the identified structural determinants to design more targeted and effective therapeutics, such as antibodies (like lecanemab) or small molecule inhibitors that specifically block the toxic features of oligomers.
  • Understanding disease nuances: Investigating how the specific properties of oligomers from different proteins contribute to the unique pathology of each disease.
  • Investigating seeding and spreading: Further exploring how these oligomers might influence the formation and spread of new toxic species.

Summary updated

Abstract

The aberrant misfolding and aggregation of peptides and proteins into amyloid aggregates occurs in over 50 largely incurable protein misfolding diseases. These pathologies include Alzheimer's and Parkinson's diseases, which are global medical emergencies owing to their prevalence in increasingly aging populations worldwide. Although the presence of mature amyloid aggregates is a hallmark of such neurodegenerative diseases, misfolded protein oligomers are increasingly recognized as of central importance in the pathogenesis of many of these maladies. These oligomers are small, diffusible species that can form as intermediates in the amyloid fibril formation process or be released by mature fibrils after they are formed. They have been closely associated with the induction of neuronal dysfunction and cell death. It has proven rather challenging to study these oligomeric species because of their short lifetimes, low concentrations, extensive structural heterogeneity, and challenges associated with producing stable, homogeneous, and reproducible populations. Despite these difficulties, investigators have developed protocols to produce kinetically, chemically, or structurally stabilized homogeneous populations of protein misfolded oligomers from several amyloidogenic peptides and proteins at experimentally ameneable concentrations. Furthermore, procedures have been established to produce morphologically similar but structurally distinct oligomers from the same protein sequence that are either toxic or nontoxic to cells. These tools offer unique opportunities to identify and investigate the structural determinants of oligomer toxicity by a close comparative inspection of their structures and the mechanisms of action through which they cause cell dysfunction.This Account reviews multidisciplinary results, including from our own groups, obtained by combining chemistry, physics, biochemistry, cell biology, and animal models for pairs of toxic and nontoxic oligomers. We describe oligomers comprised of the amyloid-β peptide, which underlie Alzheimer's disease, and α-synuclein, which are associated with Parkinson's disease and other related neurodegenerative pathologies, collectively known as synucleinopathies. Furthermore, we also discuss oligomers formed by the 91-residue N-terminal domain of [NiFe]-hydrogenase maturation factor from <i>E. coli</i>, which we use as a model non-disease-related protein, and by an amyloid stretch of Sup35 prion protein from yeast. These oligomeric pairs have become highly useful experimental tools for studying the molecular determinants of toxicity characteristic of protein misfolding diseases. Key properties have been identified that differentiate toxic from nontoxic oligomers in their ability to induce cellular dysfunction. These characteristics include solvent-exposed hydrophobic regions, interactions with membranes, insertion into lipid bilayers, and disruption of plasma membrane integrity. By using these properties, it has been possible to rationalize in model systems the responses to pairs of toxic and nontoxic oligomers. Collectively, these studies provide guidance for the development of efficacious therapeutic strategies to target rationally the cytotoxicity of misfolded protein oligomers in neurodegenerative conditions.
BibTeX
@inproceedings{limbocker2023characterization,
  author = {Ryan Limbocker and Nunilo Cremades and Roberta Cascella and Peter M. Tessier and Michele Vendruscolo and Fabrizio Chiti},
  title = {{Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases}},
  booktitle = {Accounts},
  year = {2023},
  doi = {10.1021/acs.accounts.3c00045},
}
Figure